Improved Outcomes After Reinforced Radial Meniscus Repair Augmented With Bone Marrow Aspirate Concentrate
Patrick A. Massey, Gabriel Sampognaro, Ellie Starnes, Michael Lowery, Macey Duncan, William F. Sherman, Andrew S. Zhang
Abstract
Purpose To assess clinical outcomes of patients who have undergone surgical repair of radial meniscal tears with reinforced suture bar (rebar) technique augmented with bone marrow aspirate concentrate. Methods This is a retrospective study of a single fellowship‐trained sports medicine surgeon's experience on all patients who underwent a reinforced repair (rebar) of a radial meniscus tear from November 2016 to 2018, with a minimum of 12‐month follow‐up. Lysholm scores, IKDC (International Knee Documentation Committee) Subjective Knee Form scores, and Tegner scale were collected postoperatively at periods for at least 1 year and retrospectively studied. Results Patients were followed for an average of 36.3 ± 25.0 months [range: 12.0‐69.0 months]. Pain scores improved from 6.1 ± 2.1 to 0.4 ± 1.4 at 1 year ( P < .001). IKDC Subjective Knee Form scores improved from 63 ± 26 to 90 ± 13 ( P = .021). Lysholm scores improved from 64 ± 28 to 94 ± 9 ( P = .025). Based on a calculated minimal clinical important difference (MCID) of 1.5, 100% of patients had improvement above the MCID. In addition, 88% of patients had a 1‐year IKDC Subjective Knee Form score above the patient acceptable symptomatic state. Preoperative Tegner activity scale improved from 3 ± 1.5 to 8 ± 2.6 ( P = .007). Patients returned to their preinjury activity with little difference in the Tegner activity scale when we compared preinjury and 1‐year postoperative (8.1 ± 1.3 vs 8.0 ± 2.6 respectively, P = .317). Conclusions The rebar repair technique for radial meniscus tears, with bone marrow aspirate concentrate augmentation, showed improved outcomes in both pain and function at minimum follow‐up of 12 months. Patients were able to return to a high preinjury activity level by 1 year, and 100% of patients had improvement above the MCID and 88% met patient acceptable symptomatic state. Level of Evidence Level IV, therapeutic case series.